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Introduction We aimed to develop and validate a self-reported QUAlity of Life Assessment in Spina bifida 
for Teenagers (QUALAS-T). 
Material and methods We drafted a 46-question pilot instrument using a patient-centered comprehen-
sive item generation/refinement process. A group of 13–17 years olds with spina bifida (SB) was recruited 
online via social media and in person at SB clinics (2013–2015). Healthy controls were recruited during 
routine pediatrician visits. Final questions were identified based on clinical relevance, factor analysis and 
domain psychometrics. Teenagers with SB completed the validated generic Kidscreen-27 instrument. 
Results Median age of 159 participants was 15.2 years (42.0% male, 77.4% Caucasian), similar to 58 con-
trols (p ≥ 0.06). There were 102 online and 57 clinic participants (82.8% of eligible). Patients, parents and 
an expert panel established face and content validity of the 2-domain, 10-question QUALAS-T. Internal 
consistency and test-retest reliability were high for the Family and Independence and Bladder and Bowel 
domains (Cronbach's alpha: 0.76–0.78, ICC: 0.72–0.75). The Bladder and Bowel domain is the same for 
QUALAS-T , QUALAS-A for adults and QUALAS-C for children. Correlations between QUALAS-T domains 
were low (r = 0.34), indicating QUALAS-T can differentiate between distinct HRQOL components. Correla-
tions between QUALAS-T and Kidscreen-27 were also low (r ≤0.41). QUALAS-T scores were lower  
in teenagers with SB than without (p <0.0001).
Conclusions QUALAS-T is a short, valid HRQOL tool for adolescents with SB, applicable in clinical and 
research settings. Since the Bladder & Bowel domains for all QUALAS versions are the same, Bladder and 
Bowel HRQOL can be measured on the same scale from age 8 through adulthood.
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INTRODUCTION
Spina bifida (SB) is a common congenital anomaly of 
the central nervous system, affecting multiple organ 
systems, including bladder and bowel function [1]. 
One of the goals of SB management is optimizing 
SB-specific health-related quality of life (HRQOL), 
or the individual's perception of the impact of SB 
on his or her physical and psychosocial function-
ing [2, 3]. This is particularly important in teenag-
ers with SB as they transition to more independent 
adult care. One of the challenges to this approach 
is that no clinically useful and validated tools exist 
for this age group, especially ones that incorporate 
bladder and bowel domains [4]. Several small, single-
institutional studies published to date used limited 
and poorly validated or non-validated instruments.
[4–10] Generic HRQOL instruments validated for 
healthy teenagers[11–14] were not developed to cap-
ture the impact of SB on HRQOL or to detect clini-
cally meaningful differences in HRQOL [2].
A clinically relevant HRQOL instrument focuses on 
HRQOL specific to SB, and not physical function, is 
short and has excellent psychometric properties [2, 4]. 
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It should be developed with input from multiple 
stakeholders: teenagers, their parents, caregivers and 
healthcare providers, and should accommodate teen-
agers' cognitive and emotional development [2, 4]. 
Our goal was to develop and validate a clinically use-
ful, self-reported, disease-specific, health-related 
QUAlity of Life Assessment in Spina bifida for Teen-
agers (QUALAS-T).
MATERIAL AND METHODS
The study protocol received Internal Review Board 
approval (IRB 9470) and followed the patient-report-
ed outcome instrument development guidelines from 
the Federal Drug Administration [15]. The study 
protocol was similar to that used to develop and vali-
date QUALAS versions for adults (QUALAS-A) [16] 
and children (QUALAS-C) [17].
Eligibility and exclusion criteria
Adolescents (13–17 years old) with a history of my-
elomeniongocele or lipomeningocele requiring new-
born spine surgery were recruited either online via 
social media, or in person at outpatient multidisci-
plinary SB clinics. A questionnaire was administered 
between January 2013 and August 2015. Non-eligi-
bility criteria included: a primary diagnosis other 
than spina bifida (primary tethered cord, sacral 
agenesis, medullary lipoma, anorectal malformation, 
spinal trauma, tumor), poor self-reported English 
proficiency, developmental delay interfering with 
comprehension of questions, or surgery in the last 
month. Eligible participants were excluded if they 
did not complete the questionnaire. Eligibility and 
exclusion criteria remained unchanged for all phases 
of this study. Healthy controls without SB were re-
cruited at two local pediatrics clinics during routine 
checkup visits.
Phase 1. Item generation
QUALAS-T was developed using a comprehensive, 
patient-centered item generation and refinement 
process (Figure 1). Items (questions) were gener-
ated from a series of 10 semi-structured interviews 
with teenagers with SB and their families, a review 
of published instruments as well as the opinions 
of 20 national and international experts in SB care 
(see Acknowledgments). The item generation pro-
cess was stopped when no new items were generated, 
yielding a comprehensive list of 147 items covering 
themes of cognition, independence, emotional im-
pact, social interactions, romantic concerns, educa-
tional, work and leisure activities, mobility, health-
care interactions, toileting, as well as urinary and 
fecal continence. This exhaustive list was reduced 
to 90 items by an expert panel, which eliminated 
similarly worded and redundant items, while main-
taining the themes.
Phase 2. Development of pilot instrument
The 90 items were rated on importance by 6 teen-
agers with SB and 6 parents from our center's SB 
clinic. Ratings were made on a 3-point Likert scale 
(not important, somewhat important, very impor-
tant). After review by an expert panel, 46 items 
with the highest rankings per theme were selected 
to create a more manageable and representative pilot 
QUALAS-T. This item reduction approach has been 
successfully used in other studies in the SB popula-
tion [8, 9, 18]. Some items were reworded to ensure 
comprehension and clarity based on feedback from 
the 12 individuals rating the questions and a Health 
Phase 1: Item generation (147 items)
• Semi-structured interviews with 10 patients with SB 
and families
• Review of published instruments
• Expert opinion
Phase 3: Participant recruitment
• 58 controls without SB recruited
• 156 teenagers with SB recruited
Phase 4: Refinement of instrument
• Review by SB expert panel
• Removal of insensitive items
• Factor analysis
Phase 5: Validation of instrument
• Validity: face, content, convergent and discriminant
• Reliability: internal consistency and test-retest
Final QUALAS-T instrument (10 items)
• A valid and reliable assessment of HRQOL in teens  
with SB
Phase 2: Development of pilot instrument (46 items)
• ltems reworded and selected based on importance 
ranking by 10 patients with SB and families and expert 
opinion
Figure 1. Creation of the QUAlity of Life Assessment in Spina 
bifida in Teenagers (QUALAS-T). SB – Spina Bifida.
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Literacy Educator at our institution's Family Educa-
tion Center (see Acknowledgments). Readability was 
assessed by the Flesch Kincaid Grade Level test [19].
The pilot QUALAS-T was self-administered. Ques-
tions were close-ended and numbered to avoid 
omission. Similar to several other pediatric instru-
ments, questions reflected the last 4 weeks [9, 12, 
20]. Responses used a 5-point Likert scale (never, 
almost never, sometimes, almost always, always), 
an approach successfully used in other instruments 
[8, 9, 11, 12, 20]. Items focusing on similar themes 
were grouped together to simulate the final QUA-
LAS-T instrument.
Phase 3. Further participant recruitment
A demographic questionnaire and the pilot QUA-
LAS-T were administered anonymously to a sample 
of teenagers with SB and controls in a cross-sec-
tional survey. Teenagers with SB also completed 
the validated general Kidscreen-27 instrument [11]. 
In order to open the study to teenagers from a va-
riety of social and healthcare setting, participants 
were recruited through local and national organiza-
tions via social media (see Acknowledgments) and at 
an outpatient multidisciplinary SB clinics. Consent 
was obtained online (computer-based) or in person 
(clinic-based). Two-week test-retest reliability was 
assessed by readministering the QUALAS-T to par-
ticipants recruited in clinic. Teenagers with SB and 
controls received $5 incentive payments. Incentive 
payments were increased to $25 in the final 6 months 
of the study to encourage enrollment.
Phase 4. Refinement of instrument
A factor analysis on 46 items would require at ap-
proximately 230 participants (5 participants/item) 
for adequate statistical power [21, 22]. The study 
was closed after 32 months of recruitment despite 
not reaching 230 participants. To further refine the 
instrument, we performed a principal axes method 
of factor analysis using varimax (orthogonal) rota-
tion [23, 24]. The number of extracted factors/do-
mains was based on five criteria described previ-
ously: scree plot inflexion point, multiple models 
with different numbers of factors and 5 rotations, 
extracted factors having ≥3 variables with loadings 
≥0.4, clinical plausibility/ relevance, and statistical 
properties of each domain [16, 23, 24]. Based on 
these criteria, the final QUALAS-T instrument con-
sisted of two domains of 5 items each. QUALAS-T 
is scored 0–100, where higher values signify higher 
HRQOL, and takes less than 5 minutes to complete. 
In the event only four responses are provided for 
a 5-item domain, we suggest considering these four 
items in the domain [25].
Phase 5. Internal validation
We assessed different types of validity to ensure 
that the 10-item QUALAS-T measures what it in-
tends to measure [26]. A review by patients, fami-
lies and experts established face and content validity 
of QUALAS-T. Factor analysis additionally assessed 
construct validity. For each domain score, we calcu-
lated the mean, standard deviation (SD), median, 
range and the percentage of participants scoring 
minimum (floor) and maximum (ceiling) values. 
Reliability, or reproducibility, was assessed using 
internal consistency (Cronbach's alpha: 0.7–0.9 sig-
nifying good consistency without redundancy) [26] 
and two-week test-retest reliability (Intraclass Cor-
relation Coefficient, ICC: ≥0.7 indicating acceptable 
reliability) [27].
Conceptual independence or redundancy of QUA-
LAS-T domains was assessed with convergent and 
divergent validity. Convergent validity evaluates the 
degree to which QUALAS-T scores converge with 
other instruments measuring similar outcomes. 
On the other hand, divergent validity evaluates the 
degree to which QUALAS-T scores diverge from 
those measured by dissimilar instruments. We cal-
culated Pearson correlation coefficients (r) among 
QUALAS-T domains and with Kidscreen-27 do-
mains. To further assess divergent validity, domain 
scores between the teenagers with SB and controls 
were compared using a t-test. To quantify effect size, 
we used a previously established method of dividing 
the mean difference between teenagers with SB and 
controls by the SD of the control population [28, 29]. 
Several distribution-based approaches were used 
to determine what minimally important difference 
could be considered clinically significant. Estimated 
point differences were determined using 1/2 SD, 
[30] internal consistency and test-retest reliability, 
as previously described [31, 32]. For each domain, 
we selected the most conservative, largest point dif-
ference calculated by the three methods as the mini-
mal important score difference. A critical p = 0.05 
was used (v9.4, SAS Institute, Cary, NC).
RESULTS
Phases 1 and 2. Development of pilot instrument
The 46-item pilot instrument was developed 
in a multifaceted, patient-centered fashion (Figure 1). 
Ten semi-structured interviews lasted a mean 
of 20 minutes.
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Phase 3. Demographics
Of 110 clinic patients screened, 68 (61.8%) met eli-
gibility criteria, and 57 (83.8%) were ultimately 
enrolled (Figure 2). Of 124 online participants, 
124 (100.0%) met eligibility criteria, and 102 (82.3%) 
were enrolled. We noted no significant differences 
in gender or age between eligible teenagers who were 
and were not enrolled.
Median age of 159 participants was 15.2 years (42.0% 
male, 77.4% Caucasian), similar to 58 controls 
(p ≥0.06) (Table 1). Half of participants were com-
munity ambulators (55.0%) and 71.7% had a ven-
triculoperitoneal shunt. Most participants per-
formed clean intermittent catheterizations (77.4%) 
and 78.6% reported daytime urinary dry intervals 
of at least 4h. Participants lived in 30 states of the 
United States, encompassing 83% of the country's 
population in 2011 [33].
Phase 4. Factor Analysis
A break in the scree plot slopes on unrotated and 
varimax rotated factor analyses of 46 items suggest-
ed two meaningful factors, followed by a decreas-
ing slope of minor factors (Table 1). Similar find-
ings were obtained on the other 5 rotations. These 
two factors (Family and Independence, Bladder and 
Bowel) accounted for 46.9% of the total variance.
Phase 5. Internal validation
A review by patients, families and experts established 
content and face validity of the final 10-question QUA-
LAS-T. The Flesch Kincaid Grade Level test indicated 
a fifth grade reading level. Properties of the QUALAS-T 
domain scores were calculated, without evidence 
of floor or ceiling effects (Table 2). Each of the two 
domains had robust internal consistency (Cron-
bach's alpha: 0.76–0.78) and test-retest validity (ICC: 
0.72–0.75). The mean two-week test-retest changes 
were small for each domain (+1.9 to +4.3). Missing 
data was acceptably low for each domain (Family and 
Independence: 6.9%, Bladder and Bowel: 0.6%).
Correlations between QUALAS-T domains were 
low (r = 0.34), indicating that QUALAS-T differ-
entiates between two distinct HRQOL components 
(Table 3). Correlations between QUALAS-T and 
Kidscreen-27 domains were also low (r ≤0.41), sup-
porting the concurrent use of these instruments.
Participants with Spina Bifida
110 assessed for eligibility
42 were not eligible
38 had development  
      al delay
4 did not have spina Bifida
0 were not eligible 
0 had poor English  
   proficiency
0 were not eligible
0 had developmental
   delay
0 had poor English  
   proficiency
11 were excluded
11 did not participate
22 were excluded
22 did not complete  
questionnaire
68 were eligible
57 clinic participants
159 participants included in analysis 58 controls included in analysis
124 assessed for eligibility
124 were eligible
102 online participants
58 assessed for eligibility
Controls without Spina Bifida
Multidisciplinary Spina Bifida Clinic Online Pediatric Clinics
Figure 2. Enrollment of teenagers into the study Teenagers were enrolled at an outpatient multidisciplinary spina bifida as well as 
online via social media. Enrollment commenced in January 2013 through August 2015 (32 months). Healthy controls without SB 
were recruited from two local pediatrics clinics during routine checkup visits.
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is composed of items relevant to teenagers with SB, 
their families and clinicians, including items relating 
to intimate relationships and a comprehensive domain 
focusing on bladder and bowel dysfunction. Rather 
than treating QUALAS-T scores as absolutes, scores 
may be best compared longitudinally to the same per-
son over time, or between individuals.
QUALAS-T is the third and final of a set of short, 
age-specific HRQOL instruments meant to be self-
administered by people with SB. Both QUALAS-C 
(Children: 8–12 years old) and QUALAS-T have two 
domains of 5 items each [17]. QUALAS-A (Adults: 
≥18) has three domains of 5 items each[16]. All three 
questionnaires contain unique age-specific items ad-
dressing issues relating to esteem and independence, 
with QUALAS-A also containing items on sexual-
ity and relationships (Table 4). All three QUALAS 
questionnaires share the same Bladder and Bowel 
domain, allowing Bladder and Bowel HRQOL to be 
tracked with the same questions starting at 8 years 
old. Low rates of missing data for all QUALAS instru-
ments suggest they are not difficult to complete. Fi-
nally, for each QUALAS domain, we have established 
minimally important differences between two scores 
to reflect clinically significant differences.
Over the last 20 years, three other SB-specific 
HRQOL instruments have been developed [8, 9, 10]. 
Among these, only the Parkin et al. instrument 
has a patient-reported version for teenagers 13–18 
years old [8]. Similar to the other two other instru-
ments, the questionnaire by Parkin et al. is lengthy 
(47 items) and does not comprehensively address 
bladder and bowel care. Finally, it is unclear what 
score change, or difference, on any of these instru-
ments can be considered clinically relevant.
QUALAS-T scores for controls were significantly 
higher than teenagers with SB for both domains 
(p <0.0001), each with a large effect size (≥1.0) (Ta-
ble 2). Similar to teenagers with SB, missing data 
was low for each domain (Family and Independence: 
5.2%, Bladder and Bowel: 0.0%). Using several dis-
tribution-based approaches, we calculated the min-
imally important difference to be ≥15 for both do-
mains (range: 11.7–13.4).
DISCUSSION
We present a novel, validated HRQOL instrument de-
veloped specifically for teenagers with SB. QUALAS-T 
*Factor loading value is greater than the geometric mean (root mean square) of all 
values in the matrix. 
A similar analysis was performed on 36 other items assessed (data not shown). Each 
row represents an item scale coded on a scale of 1 = never to 5 = always. Factor loadings 
in the table are multiplied by 100 and rounded to the nearest integer.  
Table 1. Factor analysis of responses from 159 teenagers with
spina bifida
Item Factor 1 Factor 2
Having future children 63* 6
Finding a partner 60* 9
Bother by others helping 59* -1
Bother by family helping 59* -5
Doing what others can do 54* 26
Bowel wait bother 14 64*
Worry about pads being noticed 26 62*
Bowel leak bother 7 61*
Urine problems stop you from fun things 37 51*
Urine leak bother 37 40*
Table 2. Domain characteristics of the self-reported QUALAS-T in adolescents with and without spina bifida
Adolescents with spina bifida
Domain N % missing Mean (SD) Median (Range) % Scoring 
Minimum
% Scoring 
Maximum
Cronbach’s 
alpha
Test-retest  
reliability (ICC)
Family and  
Independence
148 6.9 57.0 (23.5) 60.0 (0.0-100.0) 2.0 4.1 0.76 0.75
Bladder and Bowel 158 0.6 68.5 (25.3) 70.0 (5.0-100.0) 0.0 15.8 0.78 0.72
Adolescents without spina bifida
Domain N % missing Mean (SD) Median (Range) % Scoring 
Minimum
% Scoring 
Maximum
Mean difference 
for adolescents 
with SB*
(p-value)
Effect size vs. 
adolescents with 
spina bifida**
Family and  
Independence
55 5.2 86.1 (18.8) 95.0 (20.0-100.0) 0.0 36.4 -29.4 (<0.0001)
-1.6
Large (-)
Bladder and Bowel 58 0.0 96.7 (12.0) 100.0 (20.0-100.0) 0.0 87.9 -28.3 (<0.0001)
-2.4
Large (-)
Abbreviations:  QUALAS-T: QUAlity of Life Assessment in Spina bifida for Teenagers; SD: Standard Deviation; ICC: Intraclass Correlation Coefficient.* t-test. ** Effect size was calculated 
as difference in means (spina bifida-no spina bifida) divided by the standard deviation of group without spina bifida (0.2: small, 0.5: moderate, 0.8: large effect)
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Table 3. Interscale correlations between QUALAS-T domains and the Kidscreen-27 summary scores
Table 4. Comparison of the three QUALAS questionnaires
Instrument Domain QUALAS-T Kidscreen-27
Family and  
Independence
Bladder and 
Bowel
Physical  
Well-being
Psychological-
Well-being
Autonomy 
and Parent 
Relation
Social  
Support  
and Peers
School  
Environment
Q
U
A
LA
S Family and  
Independence
1.00 – – – – – –
Bladder and Bowel 0.34 1.00 – – – – –
Ki
ds
cr
ee
n-
27
Physical Well-being 0.16d 0.21c 1.00 – – – –
Psychological Well-being 0.41 0.28b 0.37 1.00 – – –
Autonomy and  
Parent Relation
0.23c 0.31a 0.31a 0.47 1.00 – –
Social Support and Peers 0.13d 0.12d 0.32a 0.46 0.38 1.00 –
School Environment 0.24c 0.11d 0.37 0.42 0.49 0.34a 1.00
QUALAS-T – QUAlity of Life Assessment in Spina bifida for Teenagers
p < 0.0001 for all correlations, except where marked: a p ≤ 0.001, b p ≤ 0.01, c p ≤ 0.05, d p ≥ 0.10
* For this domain, the minimally important difference between two scores that represents a clinically significant difference was ≥10.  This difference was ≥15 for the 
remaining domains.
Item QUALAS-C 2.0 (8-12 years old) QUALAS-T (13-17 years old) QUALAS-A (18 years old and older)
Domain Esteem and Independence* Family and Independence Esteem and Sexuality
Embarrassment about your look X X
Dealing with health problems X
Urine catheterization bother X
Bother by family helping X X
Bother by others helping X X
Doing what others can do X
Finding a partner X
Treated differently because of health problems X
Having future children X X
Bother by sexual in/activity X
Future sexual satisfaction X
Domain Bladder and Bowel Bladder and Bowel Bladder and Bowel
Worry about pads being noticed X X X
Bother by urine leak X X X
Urine problems stop you from fun things X X X
Bother by bowel leak X X X
Bother by waiting for bowel movement X X X
Domain Health and Relationships*
Overall health X
People saw you for more than health problems X
Able to do fun things X
Time with friends X
Close friendships outside family X
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ogy: John Paul Capolicchio, MD (Montreal Children's Hospital, McGill 
University), Mohamed Elsherbini, MD (Montreal Children's Hospital, 
McGill University), Walid Farhat, MD (Hospital for Sick Children, 
University of Toronto), Richard Grady, MD (Seattle Children's Hos-
pital, University of Washington), Roman Jednak, MD (Montreal Chil-
dren's Hospital, McGill University), David B. Joseph, MD (University 
of Alabama at Birmingham), Alison C. Keenan, MD (Riley Hospital for 
Children, Indiana University Health), Martin A. Koyle, MD (Hospital 
for Sick Children, University of Toronto), Andrew L. MacNeily, MD 
(British Columbia Children's Hospital, University of British Colum-
bia), JL Pippi Salle, MD (Hospital for Sick Children, University of 
Toronto), Melissa A. Young, CPNP (Riley Hospital for Children, Indi-
ana University Health). Pediatrics: Timothy J. Brei, MD (Seattle Chil-
dren's Hospital, University of Washington), Joseph O'Neil, MD (Riley 
Hospital for Children, Indiana University Health). Clinical Pediatric 
Psychology: Khush Amaria, PhD (Hospital for Sick Children, Univer-
sity of Toronto). Health Literacy: Cynthia Latty, RN (Riley Hospital 
for Children, Indiana University Health). Statistics Consultants: 
Robert Haley, MD (University of Texas Southwestern, Dallas), Pat-
rick Monahan, PhD (Richard M. Fairbanks School of Public Health, 
Indiana University, Indianapolis). Participant Recruitment: Ahmad 
H. Bani-Hani, MD, (Alfred I. duPont Hospital for Children, Thomas 
Jefferson University), Robin Bowman, MD (Lurie Children's Hospital 
of Chicago, Northwestern University), Timothy J. Brei, MD (Seattle 
Children's Hospital, Seattle Children's Hospital), David J. Chalmers, 
MD (Maine Medical Center), Dominic C. Frimberger, MD (The Chil-
dren's Hospital of Oklahoma, University of Oklahoma), Betsy Hop-
son, MSHA (Children's Hospital of Alabama, University of Alabama at 
Birmingham), Jill Mazurek, MD (Indiana University Health), Audrey 
Rhee, MD (Cleveland Clinic Children's Hospital, Cleveland Clinic Le-
rner College of Medicine of Case Western Reserve University), Bran-
don G. Rocque, MD (Children's Hospital of Alabama, University of 
Alabama at Birmingham), Dorota A. Szczepaniak, MD (Riley Hospi-
tal for Children, Indiana University Health), Gino J. Vricella, MD (St 
Louis Children's Hospital, Washington University), Hadley Wood, MD 
(Cleveland Clinic, Cleveland Clinic Glickman Urological and Kidney 
Institute). Record Entry and Review: Sable Amstutz, MD (Indiana 
University Health), Kyle Hardacker (Indiana University Health), Zoe 
King (Indiana University Health), Sophie Mazurek (Indiana Univer-
sity Health), Meredith Metcalf, MD (University of Tennessee Health-
Sciences Centre). Organizations assisting in participant recruitment: 
International Federation for Spina Bifida and Hydrocephalus and the 
Spina Bifida Association (United States), as well as: Spina Bifida Asso-
ciations of Alabama, the Carolinas, Community of Memphis, Connect-
icut, Georgia, Greater New England, Illinois, Indiana, Kentucky, Nas-
sau County, New Orleans, North Texas, Texas, Washington, Western 
Pennsylvania, Wisconsin, SB Resource Network, Spina Bifida Connec-
tion, National Birth Defects Prevention Network, Disabled Children 
of Vietnam Veterans. Research support: Funding was provided by the 
Indiana University School of Medicine's Department of Urology.
Another reason for developing QUALAS-T was that 
generic HRQOL instruments developed for teenag-
ers without SB, such as Kidscreen, [11] fail to cap-
ture aspects of HRQOL important to teenagers with 
SB. As the concept of HRQOL may vary between 
individuals with and without SB, QUALAS-T scores 
of ‘healthy controls’ are therefore likely of no clinical 
relevance and were used only to calculate validation 
statistics in this study.
Our study has several limitations. Despite an aggres-
sive recruitment strategy over a prolonged 32-month 
period, we recruited only 2/3 of the ambitious 230 
teenagers planned for a well-powered factor analy-
sis. Nonetheless, this large sample of adolescents 
with SB is one of the largest in the literature and, we 
believe, did not impair the statistical analysis, as the 
results were consistent on all analyses performed.
Study participants may have had fewer develop-
mental and functional limitations than the general 
SB population. In addition, selection bias of eli-
gible participants is unlikely to have played a sig-
nificant role, as eligible adolescents who were and 
were not enrolled had similar characteristics. While 
we did not use anchor-based methods to calculate 
minimally important differences, distribution- and 
anchor-based methods have been shown to give 
comparable results [34]. Finally, since this was vali-
dation study, risk factors for lower HRQOL were 
not investigated.
CONCLUSIONS
QUALAS-T is a short, validated tool for evaluating 
HRQOL in adolescents with SB, making it a useful 
instrument in both clinical and research settings. 
Since the Bladder and Bowel domains for QUALAS-T 
and QUALAS-A are the same, this aspect of SB-
specific HRQOL can be measured on the same scale 
after age 13 and into adulthood.
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